ea0068p37 | Abstracts | UKINETS2019
Farhad Mustafa
, Chotai Heena
, Ganatra Rakesh
, Rowley Lisa
Patients with neuroendocrine disease now have the option of having peptide receptor radionuclide therapy (PRRT) for both symptomatic treatment and reducing disease progression. Lutetium (177Lu) oxodotreotide is funded centrally in the UK and several sites have recently begun to provide the treatment for their patients. There are, however, several logistical, operational and regulatory obstacles which must be navigated to ensure the service is both safe and efficient...